Veoza Astellas Pharma Europe B.V. · Authorised · authorised 7 Dec 2023 · ATC G02CX06
Therapeutic indication (EMA)
Veoza is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Active substance
Fezolinetant
- US FDA 1
- EMA 1
- Health Canada 1
- US price lines 1
- NHS prices 1
- Safety 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VEOZAH | 45MG | tablet · oral | ASTELLAS | Prescription | 12 May 2023 |
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| VEOZAH | 02553600 | 45 MG | TABLET · ORAL | ASTELLAS PHARMA CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | VEOZAH 45 MG TABLET | $18.58225 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Fezolinetant 45mg tablets | £44.80 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- MHRA 10 Apr 2025 Fezolinetant▼(Veoza): risk of liver injury; new recommendations to minimise risk
Fezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. Liver function should be monitored before and during treatment in all patients taking fezolinetant. Fezolinetant should be avoided in patients with known liver disease or at a higher risk of liver disease. - US FDA 16 Dec 2024 VEOZAH — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.